BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.

Life sciences money is seemingly growing on trees this year. Here’s who picked a good harvest this week.

Cold Storage and Distribution Expansions Support Vaccine and Biologics Supply Chain, Keep Pace With Global Industry Trends

SUNFISH Part 2 study population includes broad range of ages and disease severities, representing a real-world spectrum of people living with Type 2 or 3 SMA

Alchemab using unique approach to explore adaptive immunity - identifying naturally protective antibodies in ‘resilient patients’ to specific diseases

- Patients treated with mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints compared to placebo - LUCENT-1 is the first and only Phase 3 study of an anti-IL-23p19 monoclonal antibody to demonstrate reduced bowel urgency in moderate to severe ulcerative colitis - Safety results in this study were consistent with that of the previous mirikizumab study in ulcerative colitis and studies with the anti-IL-23p19 antibody class

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced it has completed enrollment for its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay.

FibroGen, Inc. announced the initiation of LELANTOS-2, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with ambulatory Duchenne muscular dystrophy.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced it will host a Virtual Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to 3:00pm ET.